BCA
YMAB

Berman Capital Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History

Berman Capital Advisors’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-105
Closed -$4K – 1799
2020
Q2 		$4K Buy
+105
New +$3.97K ﹤0.01% 1091

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Berman Capital Advisors's YMAB Position: Q3 2020 in Review

Berman Capital Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q3 2020, closing a stake of 105 shares — an estimated $4K sold.

Berman Capital Advisors first reported a position in YMAB in Q2 2020 and held it in 1 quarter. The position peaked at $4K in Q2 2020. 106 funds tracked by Wall St. Rank hold YMAB as of Q3 2020.

  • Berman Capital Advisors reported no remaining Y-mAbs Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Berman Capital Advisors sold 105 Y-mAbs Therapeutics shares in Q3 2020, an estimated $4K.
  • Berman Capital Advisors first reported a position in Y-mAbs Therapeutics in Q2 2020 and held it in 1 quarter.
  • Berman Capital Advisors's Y-mAbs Therapeutics position peaked at $4K in Q2 2020.
  • 106 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2020.

Based on Berman Capital Advisors's 13F filing for Q3 2020, filed 5 Nov 2020.